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Background: The DEL blood type, a very weak D variant, is a major concern in the field of 
transfusion medicine because of its potential to cause anti-D alloimmunization. We inves-
tigated the molecular basis of serologically D-negative phenotypes, including the DEL type, 
and the distribution of other blood group systems in the Korean population using the re-
cently developed multiplex ligation-dependent probe amplification (MLPA) assay.
Methods: Blood group genotyping using the MLPA assay and RhCE phenotyping were 
performed on randomly selected 95 D-negative red blood cell products. The MLPA results 
were verified by multiplex PCR for the RHD promoter, exons 4, 7, and 10 and by direct 
sequencing of RHD exon 9.
Results: Out of 95 cases, total deletion of the RHD was observed in 74 cases (77.9%) 
and four cases (4.2%) had an RHD-CE-D hybrid allele. The other 17 cases (17.9%) had 
an RHD(1227G>A) allele, which was further confirmed by sequencing analysis. The 
RhCE phenotypes of RHD(1227G>A) alleles were composed of 14 Cce and 3 CcEe, and 
all 60 cases of the ce phenotype were revealed to have a total deletion of the RHD. Geno-
typing results and allele distribution of the other 17 blood group systems were consistent 
with previous reports on the East Asian population. 
Conclusions: MLPA assay correctly determined RHD genotype, including RHD-CE-D hy-
brid alleles or RHD(1227G>A) allele, and other clinically relevant blood group genotypes 
in D-negative Koreans. The use of MLPA assay on serologically D-negative individuals may 
help improve transfusion safety by preventing anti-D alloimmunization. 
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INTRODUCTION
The Rh blood group D antigen is highly immunogenic in the hu-
man blood group system, and anti-D alloimmunization can cause 
severe hemolytic transfusion reactions and hemolytic disease in 
the fetus and newborn [1]. DEL type is a very weak D variant 
that cannot be detected by routine serological tests and pres-
ents as a D-negative phenotype unless adsorption and elution 
studies are performed [2, 3]. In addition, DEL type can cause 
anti-D alloimmunization despite small amounts of D antigen on 
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red blood cell (RBC) surfaces. Several cases of anti-D alloimmu-
nization resulting from RBC transfusion of DEL type have been 
reported [4-7]. Currently, about 30 RHD alleles associated with 
DEL type have been reported, showing differences in distribu-
tion based on ethnicity [2]. In Caucasians, the frequency of DEL 
type among serologically D-negative individuals is 1/1,000–1/3,000, 
and RHD(885G>T) and RHD(IVS3+1G>A) are the most com-
mon DEL alleles. In East Asians, 15–20% of serologically D-neg-
ative individuals are DEL type, and the RHD(1227G>A) allele is 
the most common [8-11].
Owing to the very low frequency of the D-negative phenotype 
(0.15%) in Korea, ‘RhD-Negative Blood Club’ was organized to 
assist the supply of D-negative blood products since 1973 [8, 
12]. However, Seo et al [12] reported that 20 individuals with 
DEL type (n=16, 14.5%), weak D (n=2, 1.8%), and partial D 
(n=2, 1.8%) were classified as D-negative among 110 RhD-
Negative Blood Club members. Therefore, the accurate deter-
mination of D variant (including DEL type) is important to pro-
tect D-negative individuals from inadvertent alloimmunization to 
the D antigen. Several RHD genotyping strategies have been 
proposed specifically for East Asians. The proposed methods 
use RHD-specific multiplex PCR for the detection of total- or 
partial deletion and are followed by PCR with sequence-specific 
priming (PCR-SSP) or exon 9 sequencing to detect DEL alleles 
[8, 12, 13]. 
Recently, a multiple ligation-dependent probe amplification 
(MLPA) assay has been developed to detect RHD variants and 
zygosity, as well as the 17 other blood group systems [14, 15]. 
Compared with previously proposed strategies, the MLPA assay 
has more advantages, as the presence, absence, and copy num-
ber of 48 blood group alleles and 112 variant alleles can be de-
termined simultaneously [14, 15]. Furthermore, unlike the most 
widely used comprehensive blood group genotyping platforms 
such as the PreciseType HEA Molecular Beadchip (Immucor, 
Warren, NJ, USA) and the Progenika ID CORE XT (Progenika 
Biopharma-Grifols, Bizkaia, Spain), the MLPA assay can detect 
four frequent DEL alleles [RHD(1227G>A), RHD(885G>T), RHD 
(3G>A), and RHD(IVS3+1G>A)] [16, 17].
The performance of the MLPA assay has not been validated 
in the East Asian population with serologically D-negative phe-
notype. In this study, we investigated the molecular basis of the 
D-negative phenotype, including the DEL type, and determined 
the distribution and prevalence of other blood group genotypes 
in the Korean population.
METHODS
1. Samples
We investigated 95 randomly selected samples of D-negative 
RBC products that were supplied by the Korea Red Cross Blood 
Service and the Hanmaum Blood Center in Korea between Au-
gust 2015 and October 2015. The D antigen status of the RBC 
products was confirmed by D typing using two different anti-D 
reagents [Bioclone (Ortho-Clinical Diagnostics, Raritan, NJ, USA) 
and Anti-D (RH1) IGM1 (Diagast, Loos, France) in the Korean 
Red Cross Blood Service; Bioclone and Bioscot (Millipore, Liv-
ingstone, UK) in the Hanmaum Blood Center], and the indirect 
antiglobulin technique (IAT) in each Blood Center. An adsorp-
tion-elution test was not performed routinely by blood centers. 
All blood samples were serotyped for C/c and E/e antigens us-
ing monoclonal anti-C, -c, -E, and -e reagents (Ortho-Clinical Di-
agnostics) with the standard tube method according to the man-
ufacturer’s recommendations. This study was approved by the 
Institutional Review Board of Severance Hospital, Yonsei Uni-
versity Health System (4-2015-0882).
2. Genomic DNA extraction
Genomic DNA was isolated using the QIAamp DSP DNA Blood 
Mini kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol, and genomic DNA concentration and purity were 
assessed using a spectrophotometer (NanoDrop 2000, Thermo 
Fischer Scientific, Waltham, MA, USA).
3. MLPA assay
We used commercial SALSA MLPA Probemixes P401-A1, P402-
A1, and P403-A1 Blood Group Genotyping kits (MRC-Holland, 
Amsterdam, the Netherlands) for the MLPA assay. The three 
probe mixes contained a total of 129 probes, which included 
104 wild type and/or mutation probes to determine the pres-
ence, absence, and copy number of the major blood group al-
leles and variant alleles. The other 25 reference probes included 
were selected from chromosomal regions supposed to be chro-
mosomally stable in diseases. All procedures were carried out 
according the manufacturer’s protocol. In brief, ligation was per-
formed using 100 ng of genomic DNA in the following steps: 
denaturation at 98°C for 5 minutes, hybridization with each 
SALSA Probemix at 60°C for 16 hours, ligation reaction by Li-
gase-65 (MRC-Holland) at 54°C for 15 minutes, and ligase in-
activation by incubation at 98°C for 5 minutes. Finally, multiplex 
PCR was performed using fluorescence-labeled universal prim-
ers, dNTPs, PCR buffer, and polymerase for 35 cycles (95°C for 
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30 seconds, 60°C for 30 seconds, 72°C for 1 minute) using a 
C1000 thermal Cycler (BioRad, Cressier, Switzerland). The frag-
ments were analyzed using an ABI 3130 Genetic Analyzer (Ap-
plied Biosystems, Foster, CA, USA) and GeneMarker 2.2 soft-
ware (SoftGenetics, State College, PA, USA). Zygosity was deter-
mined as the signal ratio between tested samples and control 
samples. 
4. Multiplex PCR and sequencing
Multiplex PCR was performed to confirm the RHD genotype of 
MLPA results classified as total RHD gene deletion, RHD-CE-D 
hybrid, and DEL type. Three exons (exon 4, 7, and 10) and the 
promoter region were selected for amplification to detect the 
RHD gene (Table 1). In each multiplex PCR reaction, a 434-bp 
fragment of the human growth hormone gene was included as 
the internal control. The PCR reactions were performed with 50–
100 ng of genomic DNA containing AccuPower PCR Premix 
(Bioneer, Daejeon, Korea) and 0.5 µM of each primer in a 20 µL 
total volume. PCR amplification was performed using a C1000 
thermal cycler (Bio-Rad) with an initial denaturation at 95°C for 
10 minutes, followed by 35 cycles of 30 seconds at 95°C, 30 
seconds at 50°C for set A or 30 seconds at 60°C for set B, and 
30 seconds at 72°C. The presence or absence of RHD exons 
and the internal control were determined by electrophoresis in a 
2% agarose gel. 
Direct sequencing of the RHD exon 9, including the exon 9-in-
tron 9 boundary, was performed in MLPA assay RHD(1227G>A)-
positive samples to verify the results. The PCR reaction was per-
formed in a 20 µL reaction mixture containing AccuPower PCR 
Premix (Bioneer), 50 ng genomic DNA, and 0.5 µM of each pri-
mer (Table 1). PCR amplification was performed at 37°C for 2 
minutes for the uracil-DNA glycosylase reaction by incubating at 
95°C for 10 minutes, followed by 35 cycles of 95°C for 30 sec-
onds, 60°C for 30 seconds, and 72°C for 60 seconds. Sequenc-
ing reactions were performed using a PRISM BigDye Terminator 
v3.1 cycle sequencing kit (Applied Biosystems). The DNA sam-
ples containing amplified products were added to Hi-Di forma-
mide (Applied Biosystems), and the mixture was incubated at 
95°C for 5 minutes, cooled for 5 minutes on ice, and then analyzed 
using an ABI Prism 3730 DNA analyzer (Applied Biosystems).
Table 1. Primers used for multiplex PCR and sequencing
Method Genomic target Nucleotide sequence Product size (bp) References
Multiplex PCR (set A) RHD exon 4 F: CCACATGAACATGATGCACA 127 [18]
R: CAAACTGGGTATCGTTGCTG
RHD exon 10 F: TAAGCAAAAGCATCCAA 186 [6]
R: ATGGTGAGATTCTCCT
Multiplex PCR (set B) RHD exon 7 F: GTTGTAACCGAGTGCTGGGGATTC 123 [19]
R: TGCCGGCTCCGACGGTATC
RHD promoter F: TCCACTTTCCACCTCCCTGC 256 [19]
R: GCAGCCAACTTCCCCTGTG
Multiplex PCR (internal control) HGH F: TGCCTTCCCAACCATTCCCTTA 434 [13]
R: CCACTCACGGATTTCTGTTGTGTTTC
Sequencing RHD exon 9 F: AGATACTGTCGTTTTGACACACAAT 463 In this study
R: GCTGAGGACTGCAGATAGGG
Table 2. RhCE phenotype and RHD analysis using the MLPA assay 
Type of RHD variation RHD allele RhCE phenotype No. (%) of samples Subtotal (%)
RHD deletion Total deletion ce 60 (63.2) 74 (77.9)
cEe 9 (9.5)
Cce 5 (5.3)
RHD-CE-D hybrid allele RHD-CE-D/RHD- Cce 4 (4.2) 4 (4.2)
RHD allele with SNP RHD(1227G>A) Cce 14 (14.7) 17 (17.9)
CcEe 3 (3.2)
Total   95 (100)
Abbreviations: MLPA, multiplex ligation-dependent probe amplification; SNP, single nucleotide polymorphism.
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RESULTS
1. RHD and RHCE genotypes
Three RHD genotypic patterns were apparent in the MLPA anal-
ysis, and these patterns were confirmed using multiplex PCR for 
the promoter, and exons 4, 7, and 10 of RHD gene, as summa-
rized in Table 2. Among the 95 cases, total deletion of the RHD 
gene was observed in 74 cases (77.9%) where all RHD wild-
type probe combination signals were absent. Four cases (4.2%) 
contained the RHD-CE-D hybrid allele showing only the 5’-UTR 
and exon 10 of RHD gene. The remaining 17 cases (17.9%) 
showed positive signals at the 5’-UTR and exons 3, 4, 5, 6, 7, 9, 
Table 3. Genotype frequency of RBC antigens in the 95 RhD-negative samples
Blood group 
   system
Expected 
phenotypes
Genotype
Genotype 
frequency (%),  
n=95
002 MNS M+N-S+s- GYPA*01/01; GYPB*03/03 0 (0)
M+N-S+s+ GYPA*01/01; GYPB*03/04 7 (7.4)
M+N-S-s+ GYPA*01/01; GYPB*04/04 21 (22.1)
M+N+S+s- GYPA*01/02; GYPB*03/03 0 (0)
M+N+S+s+ GYPA*01/02; GYPB*03/04 6 (6.3)
M+N+S-s+ GYPA*01/02; GYPB*04/04 37 (38.9)
M-N+S+s- GYPA*02/02; GYPB*03/03 0 (0)
M-N+S+s+ GYPA*02/02; GYPB*03/04 0 (0)
M-N+S-s+ GYPA*02/02; GYPB*04/04 24 (25.3)
005 Lutheran Lu(a+b-) LU*01/01 0 (0)
Lu(a+b+) LU*01/02 0 (0)
Lu(a-b+) LU*02/02 95 (100)
006 Kell K+k- KEL*01/01 0 (0)
K+k+ KEL*01/02 0 (0)
K-k+ KEL*02/02 95 (100)
Kp(a+b-) KEL*03/03 0 (0)
Kp(a+b+) KEL*03/04 0 (0)
Kp(a-b+) KEL*04/04 95 (100)
Js(a+b-) KEL*06/06 0 (0)
Js(a+b+) KEL*06/07 0 (0)
Js(a-b+) KEL*07/07 95 (100)
008 Duffy Fy(a+b-) FY*01/01 80 (84.2)
Fy(a+b+) FY*01/02 13 (13.7)
Fy(a-b+) FY*02/02 2 (2.1)
009 Kidd Jk(a+b-) JK*01/01 25 (26.3)
Jk(a+b+) JK*01/02 48 (50.5)
Jk(a-b+) JK*02/02 22 (23.2)
010 Diego Di(a+b-) DI*01/01 0 (0)
Di(a+b+) DI*01/02 12 (12.6)
Di(a-b+) DI*02/02 83 (87.4)
Wr(a+b-) DI*03/03 0 (0)
Wr(a+b+) DI*03/04 0 (0)
Wr(a-b+) DI*04/04 95 (100)
Blood group 
   system
Expected 
phenotypes
Genotype
Genotype 
frequency (%),  
n=95
011 Yt Yt(a+b-) YT*01/01 95 (100)
Yt(a+b+) YT*01/02 0 (0)
Yt(a-b+) YT*02/02 0 (0)
013 Scianna Sc:1,-2 SC*01/01 95 (100)
Sc:1,2 SC*01/02 0 (0)
Sc:-1,2 SC*02/02 0 (0)
014 Dombrock Do(a+b-) DO*01/01 4 (4.2)
Do(a+b+) DO*01/02 15 (15.8)
Do(a-b+) DO*02/02 78 (82.1)
Jo(a-) DO*01.-05 0 (0)
Gy(a-) DO*02N.01 0 (0)
Hy(-) DO*02.-04 0 (0)
015 Colton Co(a+b-) CO*01/01 95 (100)
Co(a+b+) CO*01/02 0 (0)
Co(a-b+) CO*02/02 0 (0)
016 LW Lw(a+b-) LW*05/05 95 (100)
Lw(a+b+) LW*05/07 0 (0)
Lw(a-b+) LW*07/07 0 (0)
020 Gerbich Ge:2,3,4 GE*01/01 95 (100)
Ge:-2,3,4 GE*01.-02/01.-02 0 (0)
Ge:-2,-3,4 GE*01.-03/01.-03 0 (0)
021 Cromer Cr(a+) CROM*01/01 95 (100)
Cr(a-) CROM*-01/-01 0 (0)
022 Knops Kn(a+b-) KN*01/01 95 (100)
Kn(a+b+) KN*01/02 0 (0)
Kn(a-b+) KN*02/02 0 (0)
023 Indian In(a+b-) IN*01/01 0 (0)
In(a+b+) IN*01/02 0 (0)
In(a-b+) IN*02/02 95 (100)
024 Ok Ok(a+) OK*01/01 95 (100)
 Ok(a-) OK*01.-01/01.-01 0 (0)
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and 10 of the RHD gene and were assumed to be the non-dele-
tion type. For all the non-deletion types, only the RHD(1227G>A) 
mutation probe showed a positive signal in MLPA analysis. The 
RHD(1227G>A) mutation was further confirmed by sequenc-
ing analysis. 
Among the 95 total cases, RHCE*C/RHCE*c heterozygotes 
and RHCE*c/RHCE*c homozygotes of C/c alleles comprised 26 
(27.4%) and 69 (72.6%) cases, respectively, and RHCE*E/RHCE*e 
heterozygotes and RHCE*e/RHCE*e homozygotes of E/e alleles 
numbered 11 (11.6%) and 84 (88.4%), respectively. The most 
commonly predicted RhCE phenotype from the MLPA assay was 
ce (60, 63.2%), followed by Cce (24, 25.3%), cEe (9, 9.5%), and 
CcEe (2, 2.1%). 
2. Other blood group genotypes 
The prevalence of the other 16 blood group genotypes and ex-
pected phenotypes in the 95 RhD-negative donors are described 
in Table 3. For the MNS blood group, the numbers of cases with 
GYPA*01/01, GYPA*01/02, and GYPA*02/02 genotypes were 
28 (29.5%), 43 (45.3%), and 24 (25.3%), respectively. The num-
bers of cases with GYPB*03/04 and GYPB*04/04 genotypes 
were 13 (13.7%) and 82 (86.3%), respectively. Variants of the 
MNS blood group such as Gp.Mur or Gp.Dane were not detected. 
The most common phenotypic combination of the MNS blood 
group was M+N+S-s+ (38.9%), followed by M-N+S-s+ (25.3%) 
and M+N-S-s+ (22.1%). In the Duffy blood group, the numbers 
of cases with FY*01/01, FY*01/02, and FY*02/02 genotypes 
were 80 (84.2%), 13 (13.7%), and 2 (2.1%), respectively. In the 
Kidd blood group, the numbers of cases with JK*01/01, JK*01/02, 
and JK*02/02 genotypes were 25 (26.3%), 48 (50.5%), and 22 
(23.2%), respectively. The numbers of cases with DI*01/02 and 
DI*02/02 genotypes in the Diego blood group were 12 (12.6%) 
and 83 (87.4%), respectively. In the Dombrock blood group, the 
numbers of cases with DO*01/01, DO*01/02, and DO*02/02 
genotypes were 4 (4.2%), 15 (15.8%), and 78 (82.1%), respec-
tively. All 95 cases were homozygous for LU*02/02, KEL*02/02, 
KEL*04/04, KEL*07/07, DI*04/04, YT*01/01, SC*01/01, CO*01/01, 
LW*05/05, GE*01/01, CROM*01/01, KN*01/01, IN*02/02, and 
OK*01/01. 
DISCUSSION
The frequency of the D-negative phenotype varies from 0.5% in 
East Asians to 3-7% in Africans and 12-18% in Caucasians [20, 
21]. In Caucasians, the most common cause of the D-negative 
phenotype is a homozygous total deletion of the RHD gene, and 
other causes are rare [1]. In Africans, 67% of D-negative indi-
viduals have at least a single copy of RHD*Ψ, inactivated by a 
37-bp insertion in intron 3 and exon 4. This 37-bp duplication 
generates a reading frameshift and a premature stop codon [20]. 
Additionally, RHD-CE-D hybrid genes are relatively common in 
D-negative Africans. These hybrid genes consist of RHD exons 
1, 2, 9, and 10 and exons 4-8 from the RHCE gene, producing 
no D antigen [1, 20]. 
In Koreans, about 75% of D-negative individuals have a total 
deletion of the RHD gene, and 9-10% have RHD-CE-D hybrid 
genes. In addition, 13-16% of D-negative Koreans have the RHD 
(1227G>A) allele, which is the most common cause of the DEL 
type in East Asians [8, 12, 13]. In this study, total deletion of the 
RHD gene (74/95, 77.9%) was most commonly observed using 
the MLPA assay. Other genotypes were RHD-CE-D hybrid gene 
(4/95, 4.2%) and the RHD(1227G>A) allele (17/95, 17.9%). 
All DEL cases with the RHD(1227G>A) allele were further con-
firmed by sequencing RHD exon 9. This result indicating the 
molecular cause of the D-negative phenotype in Koreans is con-
sistent with previous reports [8, 21].
The DEL type is phenotypically determined by the absence of 
agglutination in the indirect antiglobulin test and a positive result 
in the adsorption/elution technique [3, 22]. As the sensitivity of 
the indirect antiglobulin test may vary across laboratories and 
false-positive results in adsorption/elution technique may also 
occur, it is difficult to accurately define the borderline between 
the DEL type and a true D-negative phenotype [2]. This leads to 
the necessity of RHD genotyping in blood donors, because it 
can exclude D variant (including DEL type) donors among sero-
logically D-negative blood donors [2, 20, 23, 24]. 
DEL type arises from several molecular mechanisms, includ-
ing splice site mutations, missense mutations, frame shift muta-
tions, RHD-CE-D hybrid, and partial deletion of the RHD gene 
[2, 9, 11, 25]. The most common DEL type in the East Asian 
population is caused by the RHD(1227G>A) allele. Although 
this substitution is a silent single nucleotide polymorphism, the 
substitution results in aberrant frame shift or exon deletion, and 
generates D protein with a weak antigen-presenting function [11]. 
Additionally, other alleles such as RHD(3G>A), RHD(28C>T), 
RHD(53T>C), RHD(251T>C), RHD(410C>A), and RHD(1222T 
>C) have also been identified in the East Asian population [8, 
12, 25]. However, the typical alleles that were identified in Cau-
casians, RHD(885G>T), RHD(IVS3+1G>A), RHD(1252insT), 
and RHD(IVS5-38del4) have not been found in East Asians [11]. 
In this study, all non-deletion type MLPA results were identified 
as the RHD(1227G>A) allele. Although the current MLPA assay 
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can detect only four frequent DEL alleles [RHD(1227G>A), RHD 
(885G>T), RHD(3G>A), and RHD(IVS3+1G>A)], other muta-
tion probes can be easily added according to the population-spe-
cific data on molecular causes of the DEL type (i.e. a probe to 
detect RHD(1222T>C) allele in Koreans) [8, 12, 26, 27]. 
Previous reports showed that the DEL type is highly associ-
ated with the RhC+ phenotype (Cc or CC) [2, 12, 19, 28-30]. 
Among 126 DEL cases in Taiwan, Wang et al [28] reported that 
107 (84.9%) cases were Cc and 19 (15.1%) cases were CC. 
Srijinda et al [29] also reported that 42 (84.0%) cases were Cc 
and eight (16.0%) cases were CC among 50 DEL cases in Thai-
land. This association between DEL type and RhC phenotype 
might be explained by the suppressive effect of C, where D anti-
gen density is suppressed by the C antigen [19]. Recently pub-
lished reports showed a similar distribution pattern in Korea, and 
the cc phenotype was exclusively found in D-negative individu-
als with total RHD deletion. Therefore, this study proposed the 
addition of RhCE phenotyping in the first step of a diagnostic 
approach to discriminate the D-negative phenotype from total 
RHD deletion inferred by ‘C-E-c+e+’ phenotype [12]. In this study, 
the RhC phenotype was identified as the Cc phenotype in all 
DEL cases, and the DEL allele with the cc phenotype was not 
found.
Since numerous blood group antigens can be accurately de-
termined by a single test, several comprehensive blood group 
genotyping platforms have been developed and are currently 
used in diverse situations [31]. The most important clinical util-
ity of this test is to identify donors lacking high-prevalence anti-
gens or multiple common antigens like those for rare donor pro-
grams. The frequency of the D-negative phenotype is 0.15% in 
Koreans, about 1/100th of the frequency in the Caucasian pop-
ulation [8]. Considering that the DEL type is relatively common 
in D-negative Koreans, the true D-negative individuals fall into 
the rare blood donor category. Comprehensive blood group ge-
notyping methods could be valuable tools for accurately deter-
mining the RHD genotype (including DEL type) and other blood 
group antigens in serologically D-negative Korean donors. 
In this study, we further evaluated the performance of an MLPA 
assay in 17 blood group systems other than the RHD gene, and 
the distribution data for major alleles from 17 blood group sys-
tems were similar to the previous data in the East Asian popula-
tion [27, 32]. In the MNS blood group system, the Ss genotype 
frequency showed ethnic variation. The frequencies of S/S, S/s, 
and s/s genotypes were 0.14, 0.40, and 0.46 among the Euro-
peans and 0.08, 0.12, and 0.80 among the Asians, respectively 
[1, 33]. Our findings showed similar results in that 0.14 of S/s 
genotypes, 0.86 of s/s genotypes, and no cases of SS genotype 
were identified in D-negative cases. In the Duffy blood group sys-
tem, two Fya-negative cases were encountered, similar to previ-
ous results [33]. The frequency of the Fya-negative phenotype 
in the Korean population is very low compared with that in the 
European population, and it is extremely difficult to find Fya-neg-
ative RBCs for anti-Fya alloimmunized patients [34, 35]. Other 
relevant antigens, including Lutheran, Kell, Yt, Scianna, Colton, 
LW, Gerbich, Cromer, Knops, Indian, and Ok blood group sys-
tems, are not polymorphic in the Korean D-negative individuals. 
In conclusion, the MLPA assay correctly determined RHD gen-
otype including RHD-CE-D hybrid alleles or RHD(1227G>A) al-
lele, and other clinically relevant blood group genotypes in D-neg-
ative Koreans. The use of MLPA assay in serologically D-nega-
tive individuals may help improve transfusion safety by prevent-
ing anti-D alloimmunization. 
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